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We compared the levels of the Ski oncoprotein, an inhibitor of transforming growth factor-beta (TGF-β)
signaling, in normal human keratinocytes (HKc), HPV16 immortalized HKc (HKc/HPV16), and differ-
entiation resistant HKc/HPV16 (HKc/DR) in the absence and presence of TGF-β. Steady-state Ski protein
levels increased in HKc/HPV16 and even further in HKc/DR, compared to HKc. TGF-β treatment of HKc,
HKc/HPV16, and HKc/DR dramatically decreased Ski. TGF-β-induced Ski degradation was delayed in HKc/
DR. Ski and phospho-Ski protein levels are cell cycle dependent with maximal Ski expression and
localization to centrosomes and mitotic spindles during G2/M. ShRNA knock down of Ski in HKc/DR
inhibited cell proliferation. More intense nuclear and cytoplasmic Ski staining and altered Ski localization
were found in cervical cancer samples compared to adjacent normal tissue in a cervical cancer tissue
array. Overall, these studies demonstrate altered Ski protein levels, degradation and localization in
HPV16-transformed human keratinocytes and in cervical cancer.
& 2013 Elsevier Inc. All rights reserved.Introduction
c-Ski plays an important role in diverse processes including;
proliferation, differentiation, transformation and tumor progres-
sion (Li et al., 1986; Reed et al., 2005; Colmenares and Stavnezer,
1989; He et al., 2003; Larsen et al., 1992, 1993). Both c-ski and
v-ski, a truncated version of c-ski, can induce transformation when
expressed at high levels (Colmenares et al., 1991). Increased Ski
protein has been observed in several human cancer cell lines and
cancer including melanoma (Reed et al., 2005; Fumagalli et al.,
1993; Hussein 2005; Medrano, 2003; Reed et al., 2001), colon
cancer (Buess et al., 2004) and esophageal carcinoma (Fukuchi
et al., 2004). One important mechanism by which Ski promotes
transformation is by inhibiting the transforming growth factor-
beta (TGF-β) pathway (Luo et al., 1999).
Cervical cancer is the second most common cancer in women
worldwide and infection with high-risk human papillomavirus
(HPV) drives cervical carcinogenesis (zur Hausen, 2000). HPV type
16 (HPV16) is responsible for about 50% of cervical cancers world-
wide and we have used a model system of HPV16-mediated
transformation of human epithelial cells to study the cellular
and molecular events that mark in vitro progression. In this modelll rights reserved.
and Gynecology, Stanfordsystem normal human keratinocytes (HKc) are immortalized by
transfection with a plasmid containing a dimer of HPV16 DNA
(HKc/HPV16) (Pirisi et al., 1987, 1988). HKc/HPV16 progress in vitro
towards malignancy through growth factor independent (HKc/GFI)
and differentiation resistant (HKc/DR) stages (Pirisi et al., 1988;
Zyzak et al., 1994). HKc/HPV16 are as sensitive to the growth
inhibitory effects of TGF-β as normal HKc, but become increasingly
resistant to TGF-β during in vitro progression towards the HKc/DR
stage (Creek et al., 1995). This loss of sensitivity to growth
inhibition by TGF-β is due to a partial loss of the TGF-β receptor
type 1 (TβRI) that decreases but does not entirely abolish Smad
signaling (Mi et al., 2000) [and unpublished results].
The expression of the HPV E6 and E7 oncoproteins is controlled
by the upstream regulatory region (URR) of the virus, which
contains binding sites for a myriad of transcription factors,
including nuclear factor I (NFI) (Apt et al., 1993). In previous
studies using HKc/HPV16, we reported that Ski can interact with
and increase the transcriptional activity of NFI, which increases E6
and E7 expression (Baldwin et al., 2004). On the other hand the
cytokine TGF-β promotes Ski degradation, which reduces NFI tran-
scriptional activity, and E6 and E7 expression (Baldwin et al., 2004).
In these studies we also found that Ski protein levels increased
several fold in TGF-β resistant HKc/DR compared to TGF-β sensitive
HKc/HPV16 (Baldwin et al., 2004).
The focus of the present study was to explore in detail Ski
protein levels, turnover and cellular localization in HKc/HPV16 and
HKc/DR, both in the absence and the presence of TGF-β. These
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cell cycle regulated in both HKc/HPV16 and HKc/DR and that Ski is
localized to centrosomes and mitotic spindles during mitosis.
Although basal Ski levels are much greater in HKc/DR compared
to HKc/HPV16, and while treatment with TGF-β resulted in
degradation of Ski in both HKc/HPV16 and HKc/DR, Ski degrada-
tion in response to TGF-β was delayed in HKc/DR. Finally, using
tissue arrays, we show that Ski protein levels are also increased in
cervical cancer.Results
Ski protein levels increase during in vitro progression of HPV16-
immortalized HKc and decrease following TGF-β treatment
In previous studies exploring the mechanism of TGF-β modula-
tion of HPV16 early gene expression we reported that Ski protein
levels increase during in vitro progression of HKc/HPV16 to HKc/
DR (Baldwin et al., 2004). Activation of TGF-β signaling promo-
tes Ski degradation through the ubiquitin-mediated pathway
(Le Scolan et al., 2008). HKc/DR are resistant to the antiprolifera-
tive effects of TGF-β due to a partial loss of TβRI (Mi et al., 2000),
however Ski degradation in response to TGF-β still occurs in HKc/
DR (Baldwin et al., 2004). This observation, together with addi-
tional studies in our laboratory using a Smad reporter construct
suggest that some TGF-β signaling remains intact in HKc/DR,
despite the partial loss of TβRI. To explore in more detail altera-
tions in Ski protein levels during HPV16-mediated transformation
and the modulation of Ski protein levels by TGF-β in HPV16-
transformed cells, we conducted both Western blot analysis
(Fig. 1a) and immunoﬂuorescence confocal microscopy studies
(Fig. 1b) in normal HKc, HKc/HPV16 and HKc/DR treated for 24 h
with or without TGF-β1 (40 pM). Ski protein levels increased in
HKc/HPV16 relative to normal HKc, and increased further in HKc/
DR (Fig. 1a). Immunoﬂuorescent staining and confocal microscopy
also showed that Ski levels increase markedly from normal HKc to
HKc/HPV16 to HKc/DR (Fig. 1b). Ski was found in both nuclei and
cytoplasm and no notable difference in the subcellular localization
of Ski was found between normal HKc and HKc/HPV16 or between
HKc/HPV16 and HKc/DR (Fig. 1b).
TGF-β treatment of normal HKc, HKc/HPV16, and HKc/DR
resulted in a dramatic decrease in Ski protein as shown by
Western blot analysis (Fig. 1a) and immunoﬂuorescence (Fig. 1b).
However, it should be noted that the basal levels of Ski in HKc/DR
are initially very high, so that the levels of Ski remaining in HKc/
DR following TGF-β treatment are roughly equivalent to those
found in normal HKc prior to TGF-β exposure (Fig. 1).
To explore in more detail the subcellular trafﬁcking of Ski
following TGF-β treatment, we conducted immunoﬂuorescent
staining and confocal microscopy for Ski in normal HKc and
HKc/DR treated for various times (5 to 60 min) with TGF-β
(40 pM). In normal HKc nuclear Ski relocated to the cytoplasm
by 30 min of TGF-β treatment and was mostly degraded by 60 min
(Fig. 2A). However, HKc/DR exhibited a delay in both the loss of
nuclear Ski and Ski degradation in response to TGF-β treatment
(Fig. 2B). Ski was still clearly detected in both the nucleus and the
cytoplasm in HKc/DR after 60 min of TGF-β treatment (Fig. 2B).
Ski protein and Ski phosphorylation levels increase dramatically
between the G0/G1 and G2/M phases of the cell cycle without changes
in Ski mRNA levels
The confocal microscopy studies of Ski described above used
unsynchronized cells. During the course of these studies we noticed
that cellular Ski protein levels could vary quite dramatically amongcells on the same dish, even cells in the same confocal ﬁeld. This
observation suggested that Ski protein levels vary in a cell cycle-
dependent manner. To explore whether Ski protein levels are cell
cycle-dependent, HKc/DR were synchronized by maintaining them in
growth factor-depleted medium (serum, insulin, EGF, and BPE free).
As determined by ﬂow cytometry, about 90% of HKc/DR were in G0/
G1 following 48 h of growth factor deprivation (data not shown).
Following refeeding with complete medium, S phase reached a
maximum at 20 h, while G2/M was maximal at 24 h (data not
shown). Total Ski levels in synchronized HKc/DR were determined
by Western blot in cell extracts obtained at various times after
refeeding (0 to 27 h). As shown in Fig. 3a, Ski protein levels were
lowest in HKc/DR following growth factor depletion (time 0),
increased dramatically by 6 h after refeeding, reached maximal levels
between 18 and 24 h, and then decreased. We also followed Ski
protein levels by Western blot in synchronized HKc/HPV16, with
similar results (data not shown). In addition, we followed Ski levels
by immunoﬂuorescent staining and confocal microscopy in synchro-
nized normal HKc, HKc/HPV16 and HKc/DR. Similar to our Western
immunoblot results, Ski levels were lowest following growth factor
depletion and both cytoplasmic and nuclear Ski increased dramati-
cally over a 24 h period after refeeding (data not shown).
We always detected Ski as two closely migrating bands on
Western immunoblots, consistent with Ski phosphorylation.
The slower migrating band of Ski showed the greatest increase
during cell cycle progression, suggesting that not only total protein
levels of Ski, but also phospho-Ski levels increase with cell cycle
progression (Fig. 3a). To verify Ski phosphorylation we treated
nuclear extracts collected from HKc/DR with λ-phosphatase (400
IU, 30 1C for 1 h) and then conducted Western blots for Ski.
As shown in Fig. 3b, after λ-phosphatase treatment (+PP), the
upper slower migrating band of Ski was mostly lost, consistent
with that band being a phoshorylated form of Ski. Importantly, the
slower migrating band of Ski was not affected by incubation with
λ-phosphatase and the phosphatase inhibitors NaF (50 mM) and
Na3VO4 (10 mM) (Fig. 3b, +PP+PPI).
We next explored whether the increased levels in Ski protein
that we observed during cell cycle progression could be attributed
to increased levels of Ski mRNA. Total RNA was extracted from
synchronized HKc/DR at 6 to 24 h after refeeding with complete
medium. Ski mRNA levels were determined by Real Time PCR. Ski
mRNA levels ﬂuctuated, but increased by less than 2-fold at any
point during the 24 h refeeding period (data not shown). Thus, it is
likely that the observed increase in cellular levels of Ski and
phosphorylated Ski protein as cells progress through the cell cycle
is the result of changes in the rate of Ski degradation, rather than
increased steady-state levels of Ski mRNA.
Ski protein is located in centrosomes and mitotic spindles of HKc/DR
during the G2/M phase of the cell cycle
Since we found that Ski protein levels peak at the G2/M phase
of the cell cycle, we next studied cellular localization of Ski during
G2/M. HKc/DR were synchronized in G2/M by treatment with the
microtubule inhibitor nocodazole (10 ng/ml) for 16 h. Ski protein
was then visualized by immunoﬂuorescence staining and confocal
microscopy. We found that virtually all of Ski is localized in
centrosomes and mitotic spindles in HKc/DR (Fig. 4). Similarly,
we found that Ski is localized in the centrosomes and mitotic
spindle in nocodazole-treated normal HKc (data not shown).Ski shRNA inhibits cell proliferation in HKc/DR
To further explore the possible functions of Ski, a Ski shRNA
was used to knock down Ski levels in HKc/DR. The pSUPER.retro
Fig. 1. TGF-β decreases Ski protein levels in normal HKc, HKc/HPV16 and HKc/DR. (a) Western blot of ski protein in normal HKc, HKc/HPV16 and HKc/DR. Cells were cultured
in the absence (−) or the presence (+) of TGF-β (40 pM for 24 h) and cell extracts prepared for Western blot analysis of Ski. Western analysis for TFIID was used as a loading
control. (b) Detection of Ski protein by immunoﬂuorescence in normal HKc, HKc/HPV16 and HKc/DR with or without TGF-β treatment. Cells were cultured in the absence (−)
or the presence (+) of TGF-β (40 pM for 24 h) and Ski was detected by indirect immunoﬂuorescence (green). Nuclei were stained with far red. Shown are the images for Ski
alone (green) and the merged images of Ski and nuclei (green and red).
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transfected into HKc/DR and Ski protein levels were determined
by Western blot analysis. The Ski shRNA reduced the levels of Ski
protein by about 70% (Fig. 5a). These results were conﬁrmed by
immunoﬂuorescence and confocal microscopy for Ski in HKc/DR
stably transfected with Ski shRNA vector, in comparison with those
transfected with the control pSUPER.retro (data not shown).
To assess whether knocking down Ski protein affects cell
proliferation, we compared the growth of HKc/DR transfected
with the pSUPER.retro SkiRNAi vector to those containing the
control pSUPER.retro vector by determining cell numbers every
24 h for eight days. As shown in Fig. 5b, control HKc/DR doubled
approximately every 24 h, while the proliferation of cells expres-
sing Ski shRNAi was markedly reduced.
Ski protein is overexpressed and mislocalized in cervical cancer
We used a tissue array to explore Ski protein levels in cervical
squamous cell carcinoma tissue specimens and corresponding
adjacent normal tissue specimens by immunoﬂuorescence stain-
ing and confocal microscopy. In normal cervical tissue Ski was
expressed at the highest level in the basal layer of the epithelium
and Ski protein gradually decreased in the more differentiated
layers (Fig. 6, adjacent normal cervical tissue). Also, most of the Skiwas localized to the nucleus in the normal epithelium, with some
cytoplasmic staining (Fig. 6, adjacent normal cervical tissue).
In cervical squamous cell carcinoma Ski was present through the
entire tissue and most of the Ski was localized to the cytoplasm
rather than the nucleus (Fig. 6, cervical squamous cell carcinoma).
The tissue microarray contained 80 tissue samples, including 42
cervical squamous cell carcinoma samples, and 38 adjacent
normal cervical tissue samples. Ski staining was generally more
intense in cervical squamous cell carcinoma samples than in
adjacent normal cervical tissue. Multiple images from each sample
were taken at the same settings using a confocal microscope and
images were scored from+to +++ based upon ski signal intensity
as described in Materials and methods. The results of this study
are presented in Table 1. Most of the normal tissue (about 74%) had
staining intensities of ++ or less, while almost 79% of cancers
stained +++. None of the cancers were found to have staining
intensity of +.Discussion
c-Ski is involved in diverse cellular processes ranging from
proliferation, differentiation, transformation and ultimately tumor
progression [see (Bonnon and Atanasoski, 2012) for a recent
Fig. 2. Delayed loss of nuclear Ski and Ski degradation in response to TGF-β in HKc/DR, compared to normal HKc. Cells were immunostained for Ski (green) at various times
(0 to 60 min) after treatment with TGF-β (40 pM) and nuclei visualized with far red. (a)–(f) Ski staining only (green). (a′)—(f′) merged Ski (green) and nuclei (red) staining.
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conditions such as Barrett's esophagus (Villanacci et al., 2008), as
well as numerous cancers such as pancreatic (Heider et al., 2007),
melanoma (Reed et al., 2005, 2001), esophageal (Fukuchi et al.,
2004), colorectal (Buess et al., 2004), and acute myeloid leukemia
(Ritter et al., 2006). Increased levels of Ski protein correlate to
tumor progression in esophageal cancer (Fukuchi et al., 2004) and
ampliﬁcation of the Ski gene is a negative prognostic marker in
early-stage colorectal cancer (Buess et al., 2004).
The most important function described to date for Ski is to
negatively regulate TGF-β signaling [reviewed in (Liu et al., 2001;
Deheuninck and Luo, 2009)]. Speciﬁcally Ski interacts with Smad2,Smad3, and Smad4, forming a complex that binds to Smad binding
elements (SBEs) on DNA, and represses the transcription of TGF-β
responsive genes through the recruitment of the nuclear repressor
N-CoR and mSin3a; the latter associates with histone deacetylase
(HDAC) (Luo et al., 1999; Xu et al., 2000; Sun et al., 1999; Akiyoshi
et al., 1999; Nomura et al., 1999; Suzuki et al., 2004). This is in
contrast to the interaction of Ski with nuclear factor I (NFI), which
potentiates NFI-stimulated transcriptional activation (Baldwin
et al., 2004; Tarapore et al., 1997).
A role for Ski in HPV-mediated transformation and cervical cancer
has not been investigated. In previous studies, exploring TGF-β
modulation of HPV16 early genes expression in HPV16-immortalized
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increased dramatically during in vitro progression to a differentiation
resistant phenotype (HKc/DR) (Baldwin et al., 2004). Furthermore,
HKc/DR are resistant to the antiproliferative effects of TGF-β (Creek
et al., 1995; Mi et al., 2000). In the present study we sought to explore
in detail Ski protein levels, turnover and cellular localization in HKc/
HPV16 and HKc/DR, both in the absence and the presence of TGF-β.
Both Western blot and immunoﬂorescence confocal micro-
scopy studies showed that Ski protein levels are higher in HKc/
HPV16 than normal HKc and further increased in HKc/DR. Inter-
estingly, although most functions described for Ski are nuclear, Ski
was present in both the cytoplasm and nucleus, with no large
differences in subcellular distribution as HKc/HPV16 progress to
HKc/DR. Several studies, in a variety of tumors and tumor-derived
cells, have reported Ski in the cytoplasm (Reed et al., 2001;
Fukuchi et al., 2004; Villanacci et al., 2008; Heider et al., 2007).
What function cytoplasmic Ski plays remains to be determined.
However, nuclear and cytoplasmic Ski likely modulate cellular
function differently (Nagata et al., 2006). Cytoplasmic Ski may
promote growth-promoting properties by sequestering the tumor
suppressor Rb, which is normally localized to the nucleus, in theFig. 3. Ski protein levels in HKc/DR increase throughout the cell cycle and Ski is a
phosphoprotein. (A) HKc/DR were synchronized by feeding with growth factor-free
medium (no serum, EGF, insulin, or BPE) for 48 h. Cells were then refed with
complete medium and total cell protein collected at different times (0 to 27 h)
following refeeding for detection of Ski by Western Blot. TFIID was used as a
loading control. (B) Nuclear extracts from HKc/DR were incubated in the absence
(-PP) or the presence (+PP) of λ-phosphatase for 1 h at 30 1C or in the presence of λ-
phosphatase and the phosphatase inhibitors NaF and Na3VO4 (+PP+PPI). Ski
protein was detected by Western blot and TFIID was used as a loading control.
Fig. 4. Ski protein is localized to the centrosomes and spindles in HKc/DR. HKc/DR we
detected by indirect immunoﬂuorescence (green) and nuclei were stained with DAPI (blcytoplasm (Jacob et al., 2008). In addition, cytoplasmic Ski may
interfere with TGF-β signaling by; (1) inhibiting the translocation
of Smad2 to the nucleus (Kokura et al., 2003), (2) interfering with
the phosphorylation of Smad 2 and Smad3 by the activated TGF-β
type I receptor (TβRI) (Prunier et al., 2003), and (3) interacting
directly with TβRI, forming a stable association between TβRI and
the R-Smad/Smad4 complex, and preventing the nuclear accumu-
lation of R-Smad/Smad4 (Ferrand et al., 2010).
Ski is rapidly degraded in response to TGF-β signaling through
the ubiquitin-dependent proteasome pathway via the E3 ligase
Arkadia in a Smad-dependent manner (Le Scolan et al., 2008; Sun
et al., 1999; Nagano et al., 2010). Ski is efﬁciently degraded inre treated with nocodazole for 16 h, to block the cells at prophase. Ski was then
ue). (a) Ski (green) staining only; (b) merged Ski (green) and nuclei (blue) staining.
Fig. 5. Ski Protein levels and cell proliferation are decreased by a Ski shRNA in HKc/
DR. (a) HKc/DR were stably transfected with either the pSUPER.retro vector
(Control) or a pSUPER.retro SkiRNAi plasmid, encoding a Ski shRNA (Ski shRNA).
Ski protein levels in cell extracts were determined by Western blot. TFIID was used
as a loading control. (b) HKc/DR were plated in 6-well plates in equal numbers,
transfected with either the control pSUPER.retro vector (closed circles) or the
pSUPER.retro SkiRNAi plasmid (squares), and selected with puromycin for three
days. Cell numbers were determined by manually counting the cells beginning
3 days after the end of puromycin selection.
Fig. 6. Ski protein levels increase in cervical squamous cell carcinoma. Ski protein (green) in adjacent normal cervical tissue and cervical squamous cell carcinoma tissue was
detected by indirect immunoﬂuorescence and confocal microscopy. Nuclei were stained with DAPI 405 (blue). (a) and (b) Ski staining only (green); (a′) and (b′) nuclei
staining only (blue); (a″) and (b″) merged Ski and nuclei staining.
Table 1
Distribution of staining scores for Ski among normal cervix and cervical cancer
samples. A tissue array containing 40 advanced cervical cancer samples, 2 micro-
invasive cervical cancer samples underlying normal epithelium, and 38 adjacent
normal cervix samples was stained with anti-Ski antibodies and scored as
described in Materials and methods.
Score Normal (n¼38) % Cancer (n¼42) %
+ 42.1 0
++ 31.6 21.4
+++ 26.3 78.6
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(Baldwin et al., 2004). However in HKc/DR, which are completely
resistant to the anti-proliferative effects of TGF-β, we found that
translocation of Ski from the nucleus to the cytoplasm and Ski
degradation in response to TGF-β treatment was delayed com-
pared to normal HKc.
The steady-state levels of Ski ﬂuctuate during the cell cycle,
being low during G1 and S phases and accumulating during G2/M
(Marcelain and Hayman, 2005; Macdonald et al., 2004). The cell
cycle-dependent degradation of Ski is mediated by the ubiquitin-
conjugating enzyme Cdc34 (Macdonald et al., 2004). In our
studies, we followed endogenous Ski protein levels in partially
synchronized HKc/HPV16 and HKc/DR, and found that Ski levels
reached a maximum between 18–24 h following refeeding after
growth factor depletion. Thus, Ski levels were greatest during the
G2/M phase of the cell cycle in HPV16-immortalized HKc. RNA
levels of Ski did not signiﬁcantly change in HKc/DR during a 24 h
period after refeeding synchronized cells. These results further
support the concept that alterations in Ski levels during the cell
cycle are the result of changes in Ski degradation, rather thanchanges in the rates of Ski transcription. However, we cannot rule
out changes in the rate of translation of Ski mRNA during the
cell cycle.
Ski is a phosphoprotein (Marcelain and Hayman, 2005) and two
sites of phosphorylation have been identiﬁed: serine 515 (Nagata
et al., 2010) and threonine 458 (Band et al., 2009). Phosphorylation
of Ski at serine 515 did not affect its stability or its ability to
suppress TGF-β signaling (Nagata et al., 2010). However, phosphor-
ylation of Ski at threonine 458, by Akt kinase, caused its destabi-
lization (Band et al., 2009). Ski is also a target of the serine/
threonine kinase Aurora A (Mosquera et al., 2011). In the present
studies we demonstrated that endogenous Ski was phosphory-
lated in HPV16-immortalized cells and consistent with Ski
protein levels, phosphorylation of Ski was greatest during mitosis.
It should be noted, however, that phosphatase treatment of cell
extracts did not result in a single Ski band on Western blots
(Fig. 3b), indicating that either some sites of phosphorylation
are resistant to phosphatase treatment, or that other post-
translational modiﬁcations of Ski are present. Further studies are
necessary to deﬁne the physiological signiﬁcance of Ski phosphor-
ylation in HPV-transformed cells.
These studies, which found that nuclear Ski localized to the
centrosomes and the mitotic spindle during mitosis of HKc/DR, are
in agreement with those of Marcelain and Hayman (Marcelain and
Hayman, 2005). The increased levels of Ski protein and the
increased phosphorylation of Ski found during mitosis, along with
its localization to centrosomes and the mitotic spindle, suggest
that Ski might play an important role in the mitotic process,
including chromosomal segregation. This is further supported by
the co-localization of Aurora A kinase and Ski at the centrosomal
level and Ski being a target of Aurora A phosphoryla-
tion (Mosquera et al., 2011). Interestingly, a recent report found
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aneuploidy, the result of defects in chromosome segregation and a
weakened spindle assembly checkpoint (Marcelain et al., 2012).
These results suggest that Ski not only acts as an oncogene but also
has tumor suppressor function in certain situations. This is con-
sistent with the ﬁnding that ski-deﬁcient heterozygous mice have
an increased susceptibility to chemical carcinogens (Shinagawa
et al., 2001) and that reducing Ski expression in breast and lung
cancer cells does not affect tumor growth but enhances tumor
metastasis in vivo (Le Scolan et al., 2008). In the present study we
found that knocking down Ski in HKc/DR, with a shRNA, markedly
reduced cell proliferation, likely by sensitizing the cells to growth
control by endogenous TGF-β.
One may ask what is the contribution of Ski overexpression to the
observed resistance to growth inhibition by TGF-β in HKc/DR. In this
regard, we have previously shown that loss of TβRI plays a pivotal
role, as re-expression of the receptor restores growth responses to
TGF-β in HKc/DR (Mi et al., 2000). It is likely that Ski levels increase in
HKc/DR because TGF-β signaling is reduced in these cells, and TGF-β
is known to promote Ski degradation (Baldwin et al., 2004; Le Scolan
et al., 2008; Sun et al., 1999; Nagano et al., 2010). At the same time,
however, Ski can contribute to further decreasing TGF-β signaling in
HKc/DR through its many interactions with components of the TGF-β
signaling pathway (Nagata et al., 2006; Jacob et al., 2008; Kokura
et al., 2003; Prunier et al., 2003; Ferrand et al., 2010). In addition,
increased levels of Ski are likely to promote E6/E7 expression: We
have previously demonstrated that Ski cooperates with NF1 to
increase HPV16 URR activity in HKc/HPV16 and HKc/DR, leading to
increased expression of E6 and E7 (Baldwin et al., 2004). Higher
levels of E7 lead to inactivation of Rb and, as we have previously
shown, decreased activity of the TβRI promoter (Hypes et al., 2009).
Taken together, these observations point to a role of HPV16 E6/E7 in
repressing TGF-β signaling at multiple levels, which will ultimately
lead to increased Ski levels and activity.
To our knowledge these are the ﬁrst studies that have explored
Ski protein in cervical squamous cell carcinoma tissue. Ski staining
was greater than normal tissue: about 79% of the cervical tissue
samples analyzed scored +++ for ski signal intensity, while only
26% of normal tissue samples scored +++. Furthermore, similar to
what has been found in other cancers (Reed et al., 2001; Fukuchi
et al., 2004; Villanacci et al., 2008; Heider et al., 2007), over-
expressed Ski protein in cervical cancer was localized to the
cytoplasm rather than the nucleus.
In conclusion, this is the ﬁrst study to explore Ski during HPV-
mediated transformation. We demonstrate that Ski protein levels
increase during in vitro progression of HPV16-immortalized HKc
and that Ski protein and phosphoprotein levels are regulated both
by TGF-β and the cell cycle, with Ski localized to centrosomes and
the mitotic spindle during mitosis. Finally, we show that Ski is
overexpressed and primarily localized to the cytoplasm in cervical
cancer tissue. Clearly Ski and the TGF-β pathway are in a delicate
and complicated balance promoting either cellular proliferation
and tumor growth, or invasion and metastasis. Further studies are
warranted to deﬁne more clearly the role each plays during
cervical dysplasia and progression to cervical cancer. Whether or
not Ski may be useful as a biomarker or prognostic marker in
cervical disease also warrants additional study.Materials and methods
Cell culture and cell lines
Normal HKc were isolated from neonatal foreskins and immor-
talized by transfection with a plasmid containing two head-to-tail
copies of HPV16 DNA (HKc/HPV16). Establishment andcharacteristics of the HKc/HPV16 cell lines used in this study;
including the TGF-β sensitive HKc/HPV16 and the TGF-β resistant
HKc/DR have been described in detail in our previous publications
(Pirisi et al., 1987, 1988; Zyzak et al., 1994) Normal HKc and HKc/
HPV16 were cultured in serum-free MCDB153-LB basal medium
supplemented with 5 ng/ml of epidermal growth factor (EGF), 35–
50 mg protein/ml of bovine pituitary extract (BPE), 0.2 mM hydro-
cortisone, 0.1 mM calcium chloride, 10 nM triiodothyronine, 10 mg/
ml of transferrin, 5 mg/ml of insulin, and 50 μg/ml gentamycin. This
medium will be referred to as complete medium. HKc/DR were
grown in complete medium containing 1 mM calcium chloride
and 5% fetal bovine serum (FBS). Cells were split 1:10 when
conﬂuent, and medium was changed every 48 h. The serum free
medium used to synchronize cells is complete medium without
the insulin, BPE and EGF.
TGF-β treatment and nuclear protein extractions
Normal HKc, HKc/HPV16 and HKc/DR were grown on 100-mm
tissue culture dishes to 40–50% conﬂuence and treated with or
without recombinant human TGF-β1(40 pM, R&D Systems, Min-
neapolis, MN) for 48 h. After washing with PBS, cells were scraped
from the dish and nuclear extracts prepared as described by
Baldwin et al. (2004). Nuclear extracts were aliquoted and stored
−80 1C until use. Protein concentration was determined by the DC
protein assay (Bio-Rad, Hercules, CA).
Immunoﬂuoresence and confocal microscopy
Glass coverslips were pre-coated with 50 μg/ml collagen type I
(from calf skin, Sigma, St. Louis, MO) and placed into the wells of a
24-well tissue culture plate. The following day 5000–10,000
normal HKc, HKc/HPV16, or HKc/DR were plated per coverslip
and allowed to grow until about 50% conﬂuent. Cells were then
treated with or without TGF-β (40 pM) for 24 h. Cells were then
washed with ice-cold phosphate-buffered saline (PBS) and ﬁxed
with 4% neutral paraformaldehyde in PBS for 30 min on ice. After
ﬁxation, cells were permeabilized and blocked with a solution of
5% normal rabbit serum, 0.5% bovine serum albumin, and 0.1%
Triton X-100 in PBS (blocking solution) for 45 min at room
temperature with gentle rocking. The cells were incubated with
a monoclonal anti-human Ski antibody (diluted 1:500, Cascade
Bioscience, Winchester, MA) at 41 overnight and then with an
Alexa Fluor 488 rabbit anti-mouse IgG (diluted 1:500, Molecular
Probes, Eugene, OR) at room temperature for 1 h. DNA was stained
with DAPI (Molecular Probes). The cells were viewed on a Zeiss
LSM Meta 510 confocal microscope.
Total protein extraction and western blot analysis
Lysates were prepared from cells at 70–90% conﬂuency in 100-
mm dishes. After washing three times with ice-cold PBS, cells
were incubated with RIPA (50 mM Tris–Cl pH7.5, 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) containing
protease inhibitor (0.5 mM DTT, 0.2 mM PMSF, 1 μg/ml leupeptin,
1 μg/ml pepstatin A) for 30 min on ice. Whole cell lysates were
obtained by centrifugation at 14,000x g at 4 1C for 20 min. Super-
natants were stored at −80 1C until use.
Western blots for Ski (50 μg total protein) were conducted
using a monoclonal anti-human Ski antibody (2 μg/ml, Cascade
Bioscience). Membranes were incubated with the primary anti-
body overnight at 41 with gentle rocking, rinsed, and then
incubated for 1 h at room temperature with a 1:2500 dilution of
a HRP-conjugated horse anti-mouse IgG secondary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA). Ski was visualized
using the Super Signal West Pico chemiluminescence detection kit
Y. Chen et al. / Virology 444 (2013) 100–108 107(Pierce, Rockford, IL). Bands were quantiﬁed using the Image J
program.
Cell cycle synchronization and ﬂow cytometry analysis
Cells were plated on 100-mm dishes, cultured to 50–70%
conﬂuency and then washed with PBS. The cells were synchro-
nized by feeding them with growth factor-free medium (no
insulin, PBE or EGF) for 48 h at which time they were released
from growth factor deprivation by refeeding with complete
medium. At various times after refeeding the cells were harvested
for protein extraction or ﬂow cytometery on a Beckman Coulter
Epics XL Flow Cytometer using EXPO 32 software.
λ-Phosphatase treatment
Nuclear extract (35 μg protein) was incubated with λ-pho-
sphatase (800 IU, New England Biolabs, Ipswich, MA) for 1 h at
30 1C in the presence or the absence of the phosphatase inhibitors
NaF (50 mM) and Na3VO4 (10 mM).
Realtime PCR analysis of ski mRNA
HKc/DR were synchronized as described above, released from
growth factor deprivation and total RNA harvested at various
times using an RNA Isolation Kit (Agilent Technologies, Santa
Clara, CA). RNA quality and quantity was determined on a 2100
Bioanalyzer (Agilent Technologies). Reverse transcription was
conducted using an iScript cDNA Synthesis Kit (Bio-Rad) and
real-time PCR was performed using an iCycler iQ detection system
(Bio-Rad). The Ski primers used were: forward, 5′ GCG CCT TCC
GAA AAG GAC AA 3′; reverse, 5′ GCT CTT TCT CAC TCG CTG ACA CT
3′. Control genes used were HPRT1 and GUSB3 which were rum in
parallel with Ski for each sample, and used for normalization.
The samples were run in triplicate, and the experiment was
repeated three times.
Nocodazole treatment
Normal HKc and HKc/DR were plated on 100-mm dishes and
allowed to grow to 50–80% conﬂuency. Cells were then treated
with nocodazole (10 ng/ml, Calbiochem, San Diego, CA) for 16 h at
37 1C.
Ski knock down using shRNA
The Ski shRNA used in these studies was constructed to target
Ski mRNA at nucleotide 1084. The following nucleotides were
purchased from Integrated DNA Technologies (Coralville, IA); 5′-
GAT CCC CTG AAC ACA GCC CAG GCT CTT ATT GGA AGT TCA AGA
GAC TTC CAA TAA GAG CCT GGG CTG TGT TCA TTT TTA-3′ (sense)
and 5′-AGC TTA AAA ATG AAC ACA GCC CAG GCT CTT ATT GGA AGT
CTC TTG AAC TTC CAA TAA GAG CCT GGG CTG TGT TCA GGG-3′
(antisense). The oligonucleotides were annealed and ligated to
pSUPER.retro vector (Oligoengine, Seattle, WA). HKc/DR were
transfected with the pSUPER.retro SkiRNAi vector (2.0 μg) or the
control pSUPER.retro vector (2.0 μg) using Transfast Transfection
Reagent (Promega, Madison, WI). Cells were collected 48 h after
transfection, replated, and selected with puromycin (1.0 μg/ml) for
72 h. Nuclear protein was extracted from the surviving cells and a
reduction in Ski protein levels was conﬁrmed by Western blotting.
Detection of Ski using a cervical cancer tissue array
Cervical cancer tissue arrays were obtained from US Biomax,
Inc. (Rockville, MD). Overall, 80 tissue samples are represented onthis array which includes 40 cervical squamous carcinoma speci-
mens and 40 adjacent normal cervical epithelium specimens, two
of which, however, showed inﬁltration of the stroma underlying a
relatively normal cervical epithelium by frankly cancerous cells.
Before immunostaining, antigen retrieval was conducted using
10 mM citrate acid pH 6.0 for 20 min. Monoclonal mouse anti-Ski
antibody (Cascade Bioscience) diluted 1:100 was incubated on the
slide at room temperature for 1 h. The slide was then incubated
with a 1:500 dilution of an Alexa Fluor 488 conjugated rabbit anti-
mouse secondary antibody (Santa Cruz Biotechnology) at room
temperature for 1 h. After air drying, the slide was viewed under a
confocal microscope. Images were collected and scored by three
independent reviewers. Results were compared and discrepancy
among reviewers resolved by re-examining the images together
and reaching consensus. A scoring system of +, ++ and +++ was
utilized. In addition, nuclear versus cytoplasmic localization of
staining was noted for each sample.Acknowledgments
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